Related Experiment Videos

Lisofylline: a potential lead for the treatment of diabetes

Zandong Yang1, Meng Chen, Jerry L Nadler

  • 1Department of Internal Medicine, Diabetes and Hormone Center of Excellence, Division of Endocrinology and Metabolism, University of Virginia, P.O. Box 801413, Charlottesville, VA 22908, USA. zy4q@virginia.edu

Biochemical Pharmacology
|December 14, 2004
PubMed

Insights

Lisofylline (LSF) shows promise for treating autoimmune diseases like Type 1 diabetes. This compound protects pancreatic beta cells and prevents autoimmune responses, offering new therapeutic potential.

Area of Science:

  • Immunology
  • Endocrinology
  • Pharmacology

Background:

  • Lisofylline (LSF), a methylxanthine derivative, was initially developed to reduce mortality in cancer chemotherapy-related infections.
  • LSF demonstrated inhibitory effects on phosphatidic acid and free fatty acid generation, and blocked pro-inflammatory cytokine release in various conditions.

Purpose of the Study:

  • To review recent findings on Lisofylline's (LSF) potential therapeutic applications, particularly in diabetes mellitus.
  • To explore LSF's immunomodulatory effects and its role in autoimmune disease management.

Main Methods:

  • Review of experimental studies and clinical trials investigating LSF's mechanisms of action.
  • Analysis of LSF's impact on immune cell function, cytokine production, and autoimmune responses.

Main Results:

  • LSF inhibits IL-12 signaling and cytokine production, modulating immune cell function and autoimmune responses.
  • LSF demonstrates protective effects on pancreatic beta cells and prevents autoimmune processes.
  • LSF may preserve beta cell functional mass during islet isolation.

Conclusions:

  • Lisofylline (LSF) exhibits significant potential for treating autoimmune disorders, including Type 1 diabetes.
  • LSF could be valuable in preventing autoimmune recurrence post-islet transplantation.
  • LSF offers a promising strategy for beta cell preservation and management of autoimmune conditions.

Related Concept Videos

Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...